The receptor for hepatocyte growth factor (HGF)/scatter factor (SF), Met, controls a program of invasive epithelial growth through the coordination of cell proliferation and survival, cell migration and epithelial morphogenesis. This process is important during embryogenesis and for organ regeneration in the adult. However, when deregulated the HGF/SF-Met signaling axis contributes to tumorigenesis and metastasis. Studies on the oncogenic activation of the Met receptor have shed light on the molecular mechanisms underlying the oncogenic activation of receptor tyrosine kinase (RTKs). More than a decade ago, work on the Met related oncogene, Tpr-Met, revealed the mechanism for activation of RTK-derived oncogenes generated following chromosomal translocation. More recently, studies on the mechanisms of downregulation of the Met RTK highlight a role for loss of downregulation in RTK oncogenic activation.
Discovery of Met
The Met receptor tyrosine kinase (RTK) was first identified as the product of a human oncogene, TprMet (Cooper et al., 1984; Park et al., 1986) . Tpr-Met was generated following a chromosomal rearrangement induced by the treatment of a human osteogenic sarcoma cell line with the carcinogen N-methyl-N 0 -nitronitrosoguanidine. The genomic rearrangement fuses two genetic loci, translocated promoter region, from chromosome 1q25 which encodes a dimerization leucine zipper motif, and MET, from chromosome 7q31 which contributes the kinase domain and carboxyterminus of the Met RTK Park et al., 1987) . The resulting 65 kDa cytoplasmic Tpr-Met oncoprotein forms a dimer mediated through the Tpr leucine zipper and is constitutively activated in the absence of ligand (Rodrigues and Park, 1993) (Figure 1 ). Tpr-Met is a prototype for RTK-derived oncogenes generated following chromosomal translocation. Over 25 RTK-derived oncoproteins have been identified in human tumors, all of which, where studied, possess a protein dimerization domain fused to a cytoplasmic kinase domain derived from an RTK (Rodrigues and Park, 1994; Lamorte and Park, 2001) .
The ligand for Met was identified as hepatocyte growth factor (HGF) (Bottaro et al., 1991) . HGF was originally identified as a mitogen for hepatocytes in culture (Nakamura et al., 1989; Zarnegar and Michalopoulos, 1989) . HGF is identical to scatter factor (SF), a fibroblast-derived factor that promotes dispersal of sheets of epithelial cells (Stoker et al., 1987) , as well as branching tubulogenesis of epithelia grown in threedimensional cultures (Montesano et al., 1991) . HGF/SF is thus a unique growth factor that elicits multiple cellular responses including mitogenesis, cell motility and morphogenesis (Figure 2 ). Based on shared structural homology, Met is classified as the prototype member of a RTK subfamily that also contains the Ron RTK (Ronsin et al., 1993) . The ligand for Ron, macrophage-stimulating protein, is also highly homologous to HGF as well as plasminogen, and they constitute a family with related biological activities, termed plasminogen-related growth factors.
Met and HGF/SF elicit a program of proliferative and invasive growth
HGF/SF and Met are expressed in many tissues in the adult. In vitro HGF/SF is a potent mitogen for primary hepatocytes and renal tubule cells, stimulates epithelial cell dissociation and invasion, and acts as an initiating signal for an intrinsic cellular morphogenic program of kidney, breast and lung epithelium grown in matrix culture . In vivo, HGF/SF is generally produced by mesenchymal cells and activates its receptor Met, expressed in epithelial and endothelial cells, through a paracrine mode of action (Figure 2 ). However, Met and HGF are both expressed by mesenchymal stem cells, where HGF/SF promotes the migration and proliferation of stem cells involved in tissue repair and wound healing (Neuss et al., 2004; Forte et al., 2006) , consistent with a prominent role for Met and HGF/SF in tissue repair in the adult (Michalopoulos and DeFrances, 1997; Nakamura et al., 2000; Matsumoto and Nakamura, 2001) . During embryogenesis, HGF/SF and Met are essential. Mice null for either gene die in utero, with reduced proliferation and survival of placental trophoblasts as well as hepatocytes. This is consistent with HGF/SF acting as a potent mitogen for hepatocytes in vivo and the important role of Met in liver regeneration (Borowiak et al., 2004; Huh et al., 2004) . In addition, these studies have demonstrated a role for Met and HGF/SF for the directional migration of myoblasts from the somites of the limbs and in the development and innervation of skeletal muscles, and directing the growth of axonal cones (Schmidt et al., 1995; Uehara et al., 1995; Yang and Park, 1995; Ebens et al., 1996; Maina et al., 1997) .
Met signal transduction
Tubular branching is a complex morphogenic process that requires tight coordination of cell growth, cell polarity, movement and invasion (reviewed by Pollack et al., 1998) . How Met elicits a program of epithelial remodeling and invasion, yet activates signaling pathways common to other RTKs, is poorly understood and is dependent on a prolonged signal downstream from the Met receptor. Epithelial cells, and in particular, the Met receptor in normal and tumor biology P Peschard and M Park et al., 1993; Zhu et al., 1994b) . The phosphorylation of two tyrosine residues within the carboxyl-terminus (Y1349 and Y1356) are necessary and sufficient for all biological activities of the Met receptor (Ponzetto et al., 1994; Zhu et al., 1994a; Fixman et al., 1995) , and are highly conserved between other members of the Met RTK gene family, c-Sea and Ron. These residues provide a docking site for the Grb2 and Shc adapter proteins, as well as the p85 subunit of phosphatidylinositol 3 0 kinase (PI3 0 kinase). Shc and Grb2 couple Met to the Ras-mitogen-activated protein kinase (MAPK) pathway. In addition, Grb2 acts as an adapter to indirectly recruit multiple proteins to Met. These include the Gab1 docking protein as well as the c-Cbl and Cbl-b ubiquitin ligases (Figure 1 ). Gab1 belongs to a family of docking proteins, including closely related proteins Gab2 and daughter of sevenless , as well as the more remotely related insulin receptor substrate-1, downstream of kinases, and fibroblast growth factor receptor receptor substrate 2 (reviewed in Liu and Rohrschneider, 2002 ). These proteins lack enzymatic activities. Following their recruitment to activated tyrosine kinase and cytokine receptors, they become phosphorylated on tyrosine residues, providing binding sites for multiple proteins involved in signal transduction. In this manner, they act to potentiate and diversify the signals downstream from receptors by virtue of their ability to assemble multiprotein complexes.
In epithelial cells, Gab1 is the major substrate for the Met RTK (Nguyen et al., 1997) , and genetic and cell biological studies (Maroun et al., 1999; Maroun et al., 2000 Maroun et al., , 2003 have demonstrated that Gab1 is crucial for the biological responses downstream from Met. Embryos nullizygous for Gab1 display all of the defects observed in Met or HGF/SF null embryos (Itoh et al., 2000; Sachs et al., 2000) . Although Gab1 is recruited to many RTKs indirectly via Grb2, its interaction with the Met receptor is unique as it involves both an indirect and a direct mechanism of recruitment (Weidner et al., 1996; Lock et al., 2000; Lock et al., 2002) . The direct interaction of Gab1 with Met requires 13 amino acids within the Gab1 Met binding domain (MBD) that interact directly with Y1349 present in the multisubstrate binding site on the Met C-terminus (Schaeper et al., 2000) . The Gab1 MBD does not resemble classical SH2 or PTB domains and is not conserved in other members of the Gab family. It binds to pY1349 in the Met receptor as a peptide motif and the interaction involves amino acids within the Met kinase domain and requires its structural integrity (Lock et al., 2003) . This defines a unique interaction between a RTK and its substrate. It allows a direct and robust association between Gab1 and Met, this results in sustained phosphorylation of Gab1 in response to HGF/SF and is required for the morphogenic invasive response (Maroun et al., 2000) . This in turn leads to the sustained activation of several signaling pathways recruited to Gab1. These include the tyrosine phosphatase SHP-2, the p85 subunit of PI3 0 K, PLCg, as well as the Crk adaptor protein. Activation of the Ras pathway is central to the program of invasive growth and the
PI3
0 K-dependent activation of Akt and downstream pathways, is required for cell migration and escape from apoptosis (reviewed in (Birchmeier et al., 2003) . The association of Gab1 with the SHP-2 phosphatase is necessary for the sustained activation of MAPK required for branching morphogenesis (Maroun et al., 2000; Schaeper et al., 2000; Lamorte et al., 2002b) . Met also activates pathways that modulate the actin cytoskeleton, cell adhesion and migration, including Src, Rho, Rac and PAK (Rahimi et al., 1998; Royal et al., 2000) . The activation of some of these pathways is mediated through the interaction between Gab1 and Crk, whereby Crk can couple Gab1 to Rap1 and Rac (Lamorte et al., 2002a) and is required for the breakdown of cell-cell junctions and cell dispersal, in addition to branching morphogenesis in response to HGF/SF (Lamorte et al., 2002b; Rodrigues et al., 2005) .
In addition to direct signaling, Met interacts with several cell surface proteins that cooperate to illicit a biological response. These include b-4 integrin, (Trusolino et al., 2001) , the hyaluronan receptor CD44 (OrianRousseau et al., 2002) , semaphorin (Giordano et al., 2002) and ezrin (Crepaldi et al., 1997) . Complexes between Met and b-4 integrin, have been associated with invasive growth (Trusolino et al., 2001) , whereas CD44 couples Met to the actin cytoskeleton (Orian-Rousseau et al., 2002) . In addition, Met signals cooperate with the HER-2 RTK to promote loss of epithelial polarity and organization and enhanced cell invasion, in threedimensional epithelial cell cultures, although no physical interaction between Met and HER-2 was observed (Khoury et al., 2005) . Morphogenic remodeling requires a balance in the activation of all downstream Met signals, and an imbalance in signaling pathways as activated in cancer can switch the Met signal from a morphogenic process to an invasive one.
In addition to HGF/SF, Met is the major host receptor for the InlB protein of Listeria monocytogenes (Shen et al., 2000) . Entry of L. monocytogenes into epithelial cells, endothelial cells and hepatocytes is considered to play an important role in its pathogenesis. InlB/Met interactions promotes entry of L. monocytogenes in cells that are normally nonphagocytic. This occurs through the activation of Met-dependent signaling pathways. These promote remodeling of the actin cytoskeleton required for phagocytic entry of the bacterium and involves the recruitment of PI3 0 kinase and Crk to Gab1 (Sun et al., 2005) .
HGF/SF and Met in tumorigenesis
The expression pattern of Met and HGF/SF promotes crosstalk between the epithelial and stromal compartments required for normal physiological processes (Thiery, 2003) . Under normal conditions, the activation of Met by HGF/SF is tightly regulated. Deregulation of the Met and HGF/SF signaling axis occurs in human tumors via multiple mechanisms, including coexpression of HGF/SF and Met, receptor amplification and point mutations (reviewed in Birchmeier et al., 2003; www.vai.org/HgfSf-MET and cancer) . Although rare, mutations within the kinase domain of Met have been found in both sporadic and hereditary forms of human papillary renal cancer (Schmidt et al., 1997) , whereas mutations in the juxtamembrane domain of Met are found predominantly in human gastric and lung cancers (Lee et al., 2000; . Under experimental conditions, Met receptors with these mutations are transforming in fibroblasts (Jeffers et al., 1997a; Jeffers et al., 1998; Lee et al., 2000; , some are tumorigenic in transgenic animals (Jeffers et al., 1998) , and when substituted in the germline, induce multiple types of tumors (Graveel et al., 2004) , supporting a direct role for Met in the tumorigenic process. In addition, elevated Met expression is observed in many human tumors (www.vai.org/HgfSf-MET and cancer), which may be a consequence of the tumor process resulting in transcriptional activation of Met and/or an enhanced population of progenitor cells that express Met. Met overexpression is, in general, associated with a metastatic phenotype and poor prognosis (reviewed by Birchmeier et al., 2003) . As overexpression of HGF/SF alone in mammary stroma of mice is sufficient to promote loss of organization of mammary epithelium corresponding to hyperplasia (Kuperwasser et al., 2004) , this highlights the importance of physiological levels of Met in the tumor process and as a physiological signal that can synergize with other signals such as HER2 for invasive growth (Khoury et al., 2005) .
The ability of Met to drive cells to invade and form metastases has been validated in model systems, involving transfected cells as well as transgenic animals (Rong et al., 1994; Jeffers et al., 1996; Saucier et al., 2002) . This is not dependent on mutational activation of Met, as melanomas that form in HGF/SF transgenic animals have a high-metastatic potential (Otsuka et al., 1998) and overexpression of a wild-type Met receptor causes hepatocarcinomas that are Met dependent (Wang et al., 2001) . Pathways promoting metastatic spread are considered to be the same ones involved in invasive growth regulated by Met during embryogenesis and in the mobilization of cells involved in tissue repair.
Structure-function studies have identified that recruitment of Grb2 and Shc-dependent pathways and activation of Ras are necessary and sufficient for cell transformation, tumorigenesis and metastatic spread (Fixman et al., 1996; Saucier et al., 2002) . The recruitment of Grb2, not only activates the Ras-MAPK pathway, but also recruits the docking protein Gab1 that in turn provides access to multiple downstream signaling pathways required for tumorigenesis. HGF/SF is also a potent-angiogenic factor (Grant et al., 1993) , by promoting the secretion of vascular endothelial growth factor, a positive regulator of angiogenesis, and by inhibiting the secretion of thrombospondin, a negative regulator of angiogenesis (Zhang et al., 2003; Saucier et al., 2004) . These studies have revealed that signaling through Shc is required for an angiogenic response downstream from Met and HER2 RTKs, and is essential for rapid tumor growth (Saucier et al., 2004) .
Regulation of Met downregulation: consequence for oncogenic activation
The biological consequences resulting from the activation of an RTK are determined by the duration, intensity and specificity of the signals activated downstream of the receptor. Regulation of signals occur at multiple levels, including the RTK itself. Termination of RTK signaling has been correlated with receptor dephosphorylation, degradation or sequestration from the cytoplasm. Several phosphatases have been identified that target the Met receptor. These include the receptor phosphatases DEP1 (Palka et al., 2003) and LAR, where LAR inactivates the Met receptor, resulting in contact inhibition, and thereby preventing the mitogenic response of primary rat hepatocytes (Machide et al., 2006) . In addition, Met is a target for the nonreceptor phosphatase PTP1B, and PTP1B null mice are protected from liver damage in part through elevated phosphorylation of Met (Sangwan et al., 2006) . However, the predominant pathway that acts to terminate Met signaling involves receptor internalization and subsequent degradation.
In addition to the enhanced Met signaling observed with Met overexpression or oncogenic Met receptor mutants, loss of negative regulation contributes to oncogenic activation of Met (Peschard et al., 2001) and may represent a common mechanism that contributes to oncogenic activation of other RTKs in human cancer (Peschard and Park, 2003) . The rapid removal of growth factor receptors from the cell surface, and subsequent targeting to lysosomal degradative compartments, provides a down-regulation mechanism important for preventing sustained activation of signaling pathways, which could potentially lead to cellular transformation (reviewed in Marmor and Yarden, 2004) . Receptor downregulation is dependent on RTK activation and ubiquitination (Katzmann et al., 2001; Buchberger, 2002; Davies et al., 2004) by the Cbl family of ubiquitin ligases (Joazeiro et al., 1999; Yokouchi et al., 1999; Keane et al., 1999; Thien and Langdon, 2001) .
The recruitment of the Cbl family of ubiquitin-protein ligases is required for ligand-induced degradation of many RTKs, among them the epidermal growth factor receptor (EGFR), the platelet-derived growth factor receptor, the colony-stimulating factor-1 receptor (CSF-1R) (reviewed by Thien and Langdon, 2001 ) and the Met receptor (Peschard et al., 2001 Abella et al., 2005) (Figure 3 ). Growing evidence indicates that ubiquitination of RTKs is critical for their lysosomal degradation, through their ubiquitin-dependent targeting to intralumenal vesicles of MVBs and lysosomal degradation (Urbe et al., 2000; Raiborg et al., 2002; Duan et al., 2003; Jiang et al., 2003; Yamasaki et al., 2003) . RTKs, including Met, may undergo multimonoubiquitination and Lys63-linked polyubiquitination, both of which do not form a signal for proteasomal degradation (Haglund et al., 2003; Mosesson et al., 2003; Carter et al., 2004; Huang et al., 2006) . The ubiquitinated RTKs are selectively recognized by proteins of the endocytic pathway that contain ubiquitin-interacting domains (UBA, UIM, UEV and CUE), such as Epsin, Eps15, Stam and Hrs (HGF regulated tyrosine kinase substrate) among others. These endocytic proteins promote the retention of ubiquitinated receptors within clathrin-coated subcompartments of sorting endosomes, and are involved in the recruitment of ESCRT (endosomal sorting complex required for transport) complexes, which leads to the inward vesiculation of ubiquitinated RTKs (reviewed in Raiborg et al., 2003) . Consequently, RTKs may no longer signal or be recycled to the cell surface, and end up being degraded in the lysosome (Figure 3) . The role of proteasomal degradation in the regulation of RTKs remains unclear as proteasomal inhibitors impair the trafficking of Met and EGFR to late endosomes (Longva et al., 2002; Hammond et al., 2003) .
Stimulation of the Met receptor with HGF/SF induces tyrosine phosphorylation of the receptor, and stimulation with high levels of HGF/SF leads to detectable Met receptor ubiquitination and enhanced degradation (Jeffers et al., 1997b; Kamei et al., 1999; Shen et al., 2000; Abella et al., 2005) . The juxtamembrane region of Met contains an additional docking site, Y1003, which acts as a negative regulator of Met biological activity , and that is absent in the Tpr-Met oncogene (Figure 1) . Although c-Cbl can be recruited to Met indirectly through the Grb2 adapter protein, phosphorylation of Y1003 provides a direct docking site for the SH2-like TKB domain of the Cbl ubiquitin ligases, and is required for liganddependent ubiquitination and degradation of the Met receptor (Peschard et al., 2001) . Knockdown of c-Cbl and Cbl-b prevents the ubiquitination of the Met RTK upon activation (Peschard and Park, unpublished data) indicating that Cbl recruitment is key for Met ubiquitination and degradation. Met receptor mutants uncoupled from Cbl-dependent ubiquitination, are transforming and tumorigenic, through enhanced RTKs that are not ubiquitinated can be recycled back to the plasma membrane. RTKs can be dysregulated in human tumors through several mechanisms. These include amplification and point mutation. Many like Tpr-Met are activated following chromosomal translocation, where in each case a protein dimerization motif is fused to the cytosolic kinase domain of the receptor. These proteins would not be expected to enter the endosomal pathway and hence, escape lysosomal degradation.
Met receptor in normal and tumor biology P Peschard and M Park stability of Met and sustained signaling of downstream pathways (Peschard et al., 2001; Abella et al., 2005) . Although a consensus for c-Cbl TKB domain binding has been established (D/NxpYxxD/EF), this motif is not present in Met, and instead, a DpYR motif, including Y1003, is required for the direct recruitment of the c-Cbl TKB domain and for ubiquitination of the Met receptor . The DpYR motif is conserved within Met family members, Met, Ron and Sea, as well as in Met orthologues in Puffer fish, suggesting a conserved function for this motif in Cbl recruitment and negative regulation of the Met receptor .
Loss of Cbl ubiquitylation in oncogenic RTKs
The observation that the specific uncoupling of the Met receptor from ubiquitination is associated with cell transformation, identified the importance for negative regulation of RTKs to suppress their transforming activity (Peschard et al., 2001; Peschard and Park, 2003) . Transgenic mice expressing a Met Y1003F or Y1003F/M1250T mutant, where M1250T is an activating mutation identified in papillary renal carcinomas (Schmidt et al., 1997 (Schmidt et al., , 1998 , have revealed that the uncoupling of Met from ubiquitination (Y1003F) was synergistic with the activating mutation, inducing mammary tumors with shorter latency and higher penetrance (Petkiewicz, Peschard and Park, unpublished) . This provides in vivo evidence that ubiquitination of the Met RTK is critical to regulate its normal biological functions.
Increasing number of reports support that loss of negative regulation leads to deregulation of many RTKs and other receptors in human cancer (Peschard and Park, 2003; Bache et al., 2004) . Naturally occurring somatic mutants of the Met receptor, which lead to loss of the Cbl TKB-binding site, have been identified in human lung cancers and, as a consequence, these receptors are poorly ubiquitinated and not targeted for degradation (Kong-Beltran et al., 2006) (Figure 3) . In a similar manner, the loss of the direct Cbl TKB-binding site in the CSF-1R (Mancini et al., 2002) , as well as the loss of Cbl recruitment to the Kit receptor (Herbst et al., 1995) , results in enhanced transforming activity. Multiple additional mechanisms that reduce Cbl-mediated ubiquitination of RTKs, such as enhanced Cbl degradation or sequestration, have been identified (Wong et al., 2002; Bao et al., 2003; Wu et al., 2003; Lee et al., 2004) . These observations suggest that loss of a Cbl TKB binding site may be a common mechanism that contributes to full oncogenic activation of RTKs.
RTKs are frequently activated in human tumors following chromosomal translocation. In general, this fuses a protein dimerization domain with the cytosolic kinase domain of the receptor, resulting in constitutive receptor dimerization and activation (Lamorte and Park, 2001 ). Over 25 RTK-derived fusion proteins have been identified in human tumors. In most cases, the N-terminal signal peptide, necessary for protein targeting to the membrane, is deleted in the rearranged kinase and where studied, these proteins are cytosolic (Rodrigues and Park, 1994; Lamorte and Park, 2001 ). Localization to the cytosol would preclude their entry in the endocytic pathway and hence, their lysosomal targeting and degradation (Figure 3 ). Plasma-membrane targeting allows Tpr-Met to enter the endocytic pathway and, transformation as well as protein stability, are decreased in a Cbl-dependent manner (Mak, Peschard and Park, unpublished) . Hence, the oncogenic activity of Tpr-Met is in part dependent on its ability to escape normal downregulatory mechanisms. This now provides a paradigm for many RTK-derived oncoproteins activated following chromosomal translocation. In addition to their activation through dimerization of the kinase domain, these oncoproteins are likely to escape normal mechanisms of downregulation. Through the years, studies of Tpr-Met and Met have uncovered several new mechanisms for oncogenic activation that when examined have proven to play a role in the oncogenic activation of other RTKs. No doubt additional mechanisms exist to be discovered.
